CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 60 target
Drug / intervention
ZG005 +3 moredrug
Likely dose
ZG005 20 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07099547
NCT07099547Phase 2RecruitingOn TrackUpdated 2mo ago
CompareCT.gov

A Study to Evaluate the Efficacy and Safety of ZG005 in Combination With Platinum-Based Chemotherapy as First-Line Treatment in Participants With Advanced Biliary Tract Carcinoma

Suzhou Zelgen Biopharmaceuticals Co.,Ltd·interventional·Posted Aug 1, 2025·Updated May 1, 2026

In Brief

A Phase 2 clinical trial evaluating ZG005, Tislelizumab, and 2 other interventions for Biliary Tract Carcinoma. Currently recruiting, targeting 60 participants across 1 site.

Detailed Summary

This is a randomized, open-label, phase II study evaluating first-line treatment for advanced gallbladder cancer. It aims to assess the efficacy, safety, pharmacokinetics, and immunogenicity of the ZG005 in Combination with gemcitabine and cisplatin as first-line therapy in Participants with advanced gallbladder cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBiliary Tract Carcinoma
CountriesChina
Collaborators--

Timeline

Phase 2Recruiting
202620272028
First PostedAug 1, 2025
Enrollment StartDec 2, 2025
Primary CompletionDec 1, 2027
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 11 months agoPrimary completion in 1.4 years

Interventions

ZG005drug

ZG005 20 mg/kg IV Q3W

Tislelizumabdrug

Tislelizumab 200mg IV Q3W

Gemcitabinedrug

Gemcitabine 1000mg/m\^2 Q3W. Gemcitabine will be administered on D1/D8 in every three weeks cycle.

Cisplatindrug

Cisplatin 25mg/m\^2 Q3W. Cisplatin will be administered on D1/D8 in every three weeks cycle.